Connect your AI

ANI Pharmaceuticals ANIP Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

AnaptysBio, Inc.ANAB

——

XER

Xeris Biopharma Holdings, Inc.XERS

——

Other financials

Income statement

Revenue$237.5M+20.5%

Gross profit$143.9M+16.0%

Operating income$38.9M+48.5%

Net income$29.5M+88.1%

EPS (diluted)$1.28+85.5%

Balance sheet

Cash & equivalents$311.2M+108%

Total debt$305.3M-3.5%

Total equity$562.3M+34.3%

Total assets$1.4B+10.0%

Cash flow

Operating cash flow$58.4M+66.8%

CapEx$6.1M+146%

Free cash flow$52.3M+60.8%

Valuation

Market cap$1.88B+18.3%

Enterprise value$1.87B+5.8%

P/E20.4×—

P/S2×-0.3×

Profitability

Gross margin60.8%+1.5pp

Operating margin13.4%—

Net margin10%+8.1pp

FCF margin20.7%+10.8pp

Returns & leverage

Return on equity18.8%+15.6pp

Debt / equity0.5×-0.2×

Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ANI Pharmaceuticals's operating lease right-of-use asset amortization?: ANI Pharmaceuticals (ANIP) reported operating lease right-of-use asset amortization of $453K in Q1 2026.
How has ANI Pharmaceuticals's operating lease right-of-use asset amortization changed year-over-year?: ANI Pharmaceuticals's operating lease right-of-use asset amortization increased by 0.2% year-over-year, from $452K to $453K.